@veslybea's Wegovy update promises, fact-checked

What did @veslybea actually say?

The short version: semaglutide as Ozempic did nothing for her, phentermine also failed, and now she's two injections into Wegovy and already down four pounds. She described her experience on Ozempic and phentermine as having a "food party" in her brain, meaning appetite suppression never kicked in. She's asking followers to join a weekly check-in series as she continues on Wegovy.

She's not making medical claims, not dosing anyone, and not selling anything in this clip. It reads as a genuine personal account of a frustrating trial-and-error process with weight loss medications, which is actually pretty common and worth talking about honestly.

Does the science back this up?

Yes, more than most people expect. Individual variation in GLP-1 receptor agonist response is real, documented, and poorly understood. Not everyone loses significant weight on semaglutide, and the data from the STEP trials makes this clear if you read past the averages.

In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), the mean weight loss with semaglutide 2.4mg was about 14.9% of body weight over 68 weeks. But "mean" hides a wide range. Roughly 14% of participants lost less than 5% of body weight, which in clinical terms is considered a non-response. A smaller subset lost essentially nothing. The biological reasons are still being studied, but differences in GLP-1 receptor expression, gut hormone feedback, and genetic variation in appetite-regulating pathways are all candidates. Her description of Ozempic simply not working is not unusual and not exaggerated.

Phentermine non-response is also well-documented. It works primarily through catecholamine release, and tolerance can develop within weeks (Bray, 2000, Obesity Research). Some people report minimal appetite suppression even at initiation.

What did they get wrong (or right)?

She got the core experience right. The claim that her "body ate the Ozempic" is colorful but directionally accurate: some people metabolize or respond to semaglutide differently, and this isn't a personal failure, it's pharmacology.

One thing worth flagging: Ozempic (0.5mg to 2mg) and Wegovy (up to 2.4mg) contain the same active molecule, semaglutide. They are not the same product. Wegovy's approved titration schedule goes higher than standard Ozempic doses, and the indication is specifically obesity, not type 2 diabetes. If she was on a lower Ozempic dose and is now on the full Wegovy titration, that could explain a different result. She doesn't specify her Ozempic dose, so we can't say for certain.

The four-pound loss in one week is almost certainly water weight and glycogen depletion early in the titration, not fat loss. That's not a knock on her, it's just how early GLP-1 response often looks. Real fat loss typically becomes more apparent after week four to six.

What should you actually know?

If you tried a GLP-1 and felt nothing, you are not imagining it and you are not alone. Non-response rates are real. The SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, New England Journal of Medicine) showed even stronger average results than semaglutide, and researchers are actively looking at why some patients respond to one agent and not another.

A few things worth knowing before you draw conclusions from her update:

• Four pounds in week one does not predict your total outcome. Early losses on GLP-1 medications are often fluid-related and can level off or even reverse slightly before real fat loss begins.
• Wegovy and Ozempic are not interchangeable even though they share an active ingredient. Dose ceiling and approved indication differ, and this matters clinically.
• Phentermine is a short-term stimulant-based medication, not a GLP-1, and comparing the two failures as if they tell the same story about her biology is a bit of an oversimplification. They work through completely different mechanisms.
• Anyone considering switching between these medications should be doing so under active medical supervision, not based on a TikTok check-in series, however relatable it is.

Bottom line

She's sharing a legitimate personal experience with medication non-response, which is genuinely useful for people who feel like failures when a GLP-1 doesn't work for them. The science does support the idea that individual response varies widely. The four-pound week-one number deserves some skepticism, not because she's lying, but because early scale movement on these drugs is often misleading. Follow the trend over eight to twelve weeks, not the first weigh-in.